Zosano Pharma Corporation [NASDAQ: ZSAN] gained 2.22% on the last trading session, reaching $0.58 price per share at the time. The company report on November 26, 2020 that SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline – ZSAN.
Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) and certain of its officers. The class action, filed in United States District Court for the Northern District of California, and docketed under 20-cv-07850, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Zosano securities between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), seeking to pursue claims against the Defendants under the Securities Exchange Act of 1934 (the “Exchange Act”).
If you are a shareholder who purchased Zosano securities during the class period, you have until December 28, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at email@example.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Zosano Pharma Corporation represents 102.07 million in outstanding shares, while the company has a total market value of $49.24 million with the latest information. ZSAN stock price has been found in the range of $0.5522 to $0.588.
If compared to the average trading volume of 5.83M shares, ZSAN reached a trading volume of 1790580 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Zosano Pharma Corporation [ZSAN]:
Maxim Group have made an estimate for Zosano Pharma Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 17, 2019. While these analysts kept the previous recommendation, Piper Jaffray raised their target price to Overweight. The new note on the price target was released on March 24, 2017, representing the official price target for Zosano Pharma Corporation stock. On November 11, 2015, analysts decreased their price target for ZSAN shares from 11 to 7.
The Average True Range (ATR) for Zosano Pharma Corporation is set at 0.06 The Price to Book ratio for the last quarter was 0.82.
Trading performance analysis for ZSAN stock
Zosano Pharma Corporation [ZSAN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.96. With this latest performance, ZSAN shares gained by 44.06% in over the last four-week period, additionally sinking by -40.82% over the last 6 months – not to mention a drop of -61.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZSAN stock in for the last two-week period is set at 45.01, with the RSI for the last a single of trading hit 64.93, and the three-weeks RSI is set at 46.09 for Zosano Pharma Corporation [ZSAN]. The present Moving Average for the last 50 days of trading for this stock 0.7608, while it was recorded at 0.5638 for the last single week of trading, and 0.8920 for the last 200 days.
Zosano Pharma Corporation [ZSAN]: A deeper dive into fundamental analysis
Return on Total Capital for ZSAN is now -141.21, given the latest momentum, and Return on Invested Capital for the company is -168.41. Return on Equity for this stock declined to -267.52, with Return on Assets sitting at -102.35. When it comes to the capital structure of this company, Zosano Pharma Corporation [ZSAN] has a Total Debt to Total Equity ratio set at 189.02. Additionally, ZSAN Total Debt to Total Capital is recorded at 65.40, with Total Debt to Total Assets ending up at 47.13. Long-Term Debt to Equity for the company is recorded at 128.20, with the Long-Term Debt to Total Capital now at 44.36.
Reflecting on the efficiency of the workforce at the company, Zosano Pharma Corporation [ZSAN] managed to generate an average of -$671,232 per employee.Zosano Pharma Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.40.
Zosano Pharma Corporation [ZSAN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Zosano Pharma Corporation posted -0.45/share EPS, while the average EPS was predicted by analysts to be reported at -0.47/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZSAN.
An analysis of insider ownership at Zosano Pharma Corporation [ZSAN]
There are presently around $7 million, or 15.40% of ZSAN stock, in the hands of institutional investors. The top three institutional holders of ZSAN stocks are: VANGUARD GROUP INC with ownership of 3,184,750, which is approximately 128.01% of the company’s market cap and around 0.40% of the total institutional ownership; AISLING CAPITAL MANAGEMENT LP, holding 2,718,226 shares of the stock with an approximate value of $1.58 million in ZSAN stocks shares; and MORGAN STANLEY, currently with $0.73 million in ZSAN stock with ownership of nearly 12157.313% of the company’s market capitalization.
Positions in Zosano Pharma Corporation stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 28 institutional holders increased their position in Zosano Pharma Corporation [NASDAQ:ZSAN] by around 6,022,956 shares. Additionally, 7 investors decreased positions by around 92,474 shares, while 11 investors held positions by with 6,766,315 shares. The mentioned changes placed institutional holdings at 12,881,745 shares, according to the latest SEC report filing. ZSAN stock had 14 new institutional investments in for a total of 1,683,694 shares, while 5 institutional investors sold positions of 85,039 shares during the same period.